Series A+ · Biotech
Vivacta Biotechnology: Series A+
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Funding history
Series A+ · This round$50M
Loading rounds…
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases